Montegen (Montelukast)

Montelukast, the active ingredient in Montegen, is a leukotriene receptor antagonist presented as a tablet for oral use. It helps manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in adults and children as directed by a healthcare professional.

GNH USA supplies Montegen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets.

Montegen, a leukotriene receptor antagonist, is indicated for conditions involving airway inflammation and allergic response.

Asthma: reduces frequency of wheezing episodes and improves lung function. Allergic rhinitis: alleviates nasal congestion, sneezing and itching. Exercise‑induced bronchoconstriction: prevents airway narrowing during physical activity.

Adverse reactions may occur with Montegen use.

Common Side Effects: - Headache - Abdominal pain - Nausea - Dizziness - Fatigue - Cough

Serious or Rare Side Effects: - Allergic reactions such as rash or angioedema - Mood changes including depression or suicidal thoughts - Elevated liver enzymes - Stevens‑Johnson syndrome - Severe bronchospasm

Montegen should be used with attention to specific safety considerations.

Pregnancy: Category B; use only if clearly needed. Breastfeeding: Monitor infant for possible effects. Liver disease: Use with caution; adjust if severe impairment. Concomitant phenobarbital or rifampin: May reduce drug effectiveness. Hypersensitivity: Avoid in patients with known allergy to montelukast. Store at room temperature: keep in original container, protect from moisture and heat.

Montegen may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Phenobarbital: may lower montelukast plasma levels. - Rifampin: can decrease therapeutic effect. - Strong CYP3A4 inducers: reduce drug exposure.

Moderate Interactions (Monitor Closely): - Fluconazole: may increase montelukast concentrations. - Zafirlukast: additive leukotriene blockade risk. - Warfarin: monitor INR for possible changes.